Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2784-2791

  Hsu, Ann ^a   Granneman, G Richard ^a   Cao, Guoliang ^a   Carothers, Lori ^a   Japour, Anthony ^a   El Shourbagy, Tawakol ^a   Dennis, Suzana ^a   Berg, Jeanne ^a   Erdman, Keith ^a   Leonard, John M ^a   Sun, Eugene ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; INDINAVIR; PLACEBO; RITONAVIR;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE;

EID: 0031785117     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2784     Document Type: Article

References (64)

1. Abbott Laboratories. 1998. Norvir™ product information. Abbott Laboratories, North Chicago, Ill.
2. Acosta, E. P., K. Henry, D. Weller, L. M. Page, L. Bacon, F. Rhame, I. Gilson, H. Rosenstein, T. Schacker, and C. V. Fletcher. 1997. Indinavir pharmacokinetics and relationships between exposures and antiviral effect, abstr. A-15, p. 3. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Balani, S. K., E. J. Woolf, V. L. Hoagland, M. G. Sturgill, P. J. Deutsch, K. C. Yeh, and J. H. Lin. 1996. Disposition of indinavir, a potent HIV-1 protease inhibitor, after a oral dose in humans. Drug Metab. Dispos. 24:1389-1394.
4. Bjornsson, T., R. Chiou, P. Deutsch, H. Haddix, V. Hoagland, S. Justice, M. Nessly, R. Pomerantz, M. Saag, K. Squires, H. Teppler, S. Waldman, E. Woolf, and K. C. Yeh. 1996. Pharmacokinetics of indinavir. Pharm Res. 13: S485.
5. Bruce, R. G., L. C. Munch, A. D. Hoven, R. S. Jerauld, R. Greenburg, W. H. Porter, and P. W. Rutter. 1997. Urolithiasis associated with the protease inhibitor indinavir. Urology 50:513-518.
6. Burger, D. M., P. P. Koopmans, K. Brinkman, M. Keuter, W. Dolmans, R. M. W. Hoetelmans, P. L. Meenhorst, J. W. Mulder, E. W. Wuis, and Y. A. Hekster. 1997. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir, abstr. A-19, p. 4. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. CAESAR Coordinating Committee. 1997. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 349:1413-1421.
8. Cameron, D. W., M. Heath-Choizzi, S. Kravick, R. Mills, A. Potthoff, D. Henry, The Advanced HIV Ritonavir Study Group, and J. M. Leonard. 1996. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with RTV, update, abstr. Mo.B.411. Presented at the XI International Conference on AIDS.
9. Cameron, D. W., A. Japour, J. Mellors, C. Farthing, C. Cohen, M. Markowitz, D. Poretz, S. Follansbee, D. Ho, D. M. Mahon, J. Berg, J. Nieves, Y. Xu, R. Rode, M. Salgo, J. Leonard, and E. Sun. 1998. Antiretroviral safety & durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two of follow-up, abstr. 388. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
10. Carpenter, C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 277:1962-1969.
11. Chiba, M., M. Hensleigh, J. A. Nishime, S. K. Balani, and J. H. Lin. 1996. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24: 307-314.
12. Chiou, R., P. Deutsch, A. Carides, I. Fu, G. Kwei, V. Hoagland, G. Lambert, M. Sturgill, K. C. Yeh. 1996. Indinavir absorption following extended-release formulations in man and in the dog. Pharm. Res. 13:8498.
13. Cohen, C., P. Siemon-Hryczk, R. Pilson, B. Holzknecht, K. Phillips, C. Karol, and S. Palleja. 1998. Potent and convenient Fortovase (SQV) SGC BID regimens in combination with 2 nucleosides or nelfinavir (NFV) plus 1 nucleoside in HIV-1 infected patients, abstr. 12314. In Abstracts of the 12th World Congress on AIDS.
14. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintade, A. G. Aguado, J. G. de Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. Safety, pharmacokinetics, and preliminary efficacy of RTV, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
15. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA 277:145-153.
16. Delta Coordinating Committee. 1996. Delta: a randomized double-blind trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348:283-291.
17. 50, abstr. A-16, p. 4. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Gentle, D. L., M. L. Stoller, T. W. Jarrett, J. F. Ward, K. S. Geib, and A. F. Wood. 1997. Protease inhibitor-induced urolithiasis. Urology 50:508-511.
19. Hammer, S. M., D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.
20. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD-4 lymphocytes in HIV-1 infection. Nature 373:123-126.
21. Hoof, T., T. Brandt, A. Demmer, and H. J. Stellbrink. 1997. Interaction of HIV protease inhibitors with MDR1 - competitive binding and resistance modulation, abstr. I-111, p. 263. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
22. Hsu, A., G. R. Granneman, G. Cao, L. Carothers, T. El-Shourbagy, P. Baroldi, K. Erdman, F. Brown, E. Sun, and J. M. Leonard. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther. 63:453-464.
23. Hsu, A., G. R. Granneman, M. Heath-Chiozzi, C. Wong, A. Japour, L. Manning, R. Brooks, and E. Sun. 1998. Indinavir can be taken with regular meals when taken with ritonavir, abstr. 22361. In Abstracts of the 12th World Congress on AIDS.
24. Hsu, A., G. R. Granneman, A. Molla, S. Vasavanonda, A. Japour, D. Kempf, E. Sun. 1998. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - based on in vitro model, abstr. 22350. In Abstracts of the 12th World Congress on AIDS.
25. Hsu, A., G. R. Granneman, G. Witt, C. Locks, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Niu, J.-P. Decourt, J.-B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:654-660.
26. Kempf, D., K. C. Marsh, J. Denssen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
27. Kempf, D. J., A. Molla, E. Sun, S. Danner, C. Boucher, and J. Leonard. 1997. The duration of viral suppression is predicted by the viral load during protease inhibitor therapy, abstr. 603. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
28. Kempf, D. J., K. C. Marsh, G. N. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 41:654-660.
29. Kim, R. B., M. F. Fromm, C. Wandel, B. Leake, A. J. J. Wood, D. M. Roden, and G. R. Wilkinson. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101: 289-294.
30. Kolars, J. C., W. M. Awni, and R. M. Merion. 1991. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
31. Kolars, J. C., K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. 1994. CYP 3A gene expression in human gut epithelium. Pharmacokinetics 4:247-259.
32. Kolars, J. C., P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. 1992. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1871-1878.
33. Kopp, J. B., K. D. Miller, J. A. Mican, I. M. Feuerstein, E. Vaughan, C. Baker, L. K. Pannell, and J. Falloon. 1997. Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Int. Med. 127:119-125.
34. Kumar, G. (Abbott Laboratories). Personal communication.
35. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P-450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
36. Kwei, G. Y., L. B. Novak, L. A. Hettrick, E. R. Reiss, D. Ostovic, A. E. Loper, C. Y. Lui, R. J. Higgins, I. W. Chen, and J. H. Lin. 1995. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dog. Pharm. Res. 12:884-888.
37. Lai, A. A., R. H. Levy, and R. E. Cutler. 1979. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin. Pharmacol. Ther. 24:316-323.
38. Lalezari, J., R. Haubrich, H. Burger, D. Bettie, L. Donatacci, M. P. Salgo, and the NV 14256 Study Team. 1996. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus Hivid (zalcitabine, ddC), abstr. LB.B.6033. In Abstracts of the XI International Conference on AIDS.
39. Lea, A. P., and D. Faulds. 1996. Ritonavir. Drugs 52:541-548.
40. Lee, C. G. L., M. M. Gottesman, C. O. Cardarelli, M. Ramachandra, K. T. Jeang, S. V. Ambudkar, I. Pastan, and S. Dey. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601.
41. Lin, J. H., I. W. Chen, K. J. Vastag, and D. Ostovic. 1995. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:730-735.
42. Lown, K. S., D. G. Bailey, R. J. Fontana, K. S. K. Janardan, C. H. Adair, L. A. Fortlage, M. B. Brown, W. Guo, and P. B. Watkins. 1997. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:2545-2553.
43. Markowitz, M., Y. Cao, M. Vesanen, A. Talal, D. Nixon, A. Hurley, R. O'Donovan, P. Racz, K. Tenner-Racz, and D. D. Ho. 1997. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor, abstr. LB8. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
44. Markowitz, M., M. Saag, W. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, K. Sattler, A. LaMarca, and J. M. Leonard. 1995. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine. abstr. LB7. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections.
45. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J. Chromatogr. B 704:307-313.
46. Merck & Co., Inc. 1998. Crixivan™ product information. Merck and Co., Inc., Rahway, N.J.
47. Molla, A., T. Chernyavskiy, S. Vasavanonda, J. Praestgaard, T. Lin, E. Sun, W. Kihlbrenner, and D. Kempf. 1998. Synergistic anti-HIV activity of ritonavir and other protease inhibitors in the presence of human serum, abstr. 12315. In Abstracts of the 12th World Congress on AIDS.
48. Molla, A., G. R. Granneman, and E. Sun. Recent developments in HIV protease inhibitor therapy. Antivir. Res., in press.
49. Mulder, J., N. McKinney, C. Christpherson, J. Sninsky, L. Greefield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
50. Pachl, C., J. A. Todd, D. G. Kern, P. J. Sheridan, S. J. Fong, M. Stempien, B. Hoo, D. Besemer, T. Yeghiazarian, B. Irvine, J. Kolberg, R. Kokka, P. Neuwald, and M. S. Urdea. 1995. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:446-454.
51. Paine, M. F., D. D. Shen, K. L. Kunze, J. D. Perkins, C. L. Marsh, D. M. Barr, B. S. Gillies, and K. E. Thummel. 1996. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60:14-24.
52. Pedersan, C., J. Gerstoft, J. O. Lunnogren, L. Mathiesen, O. Kirk, H. Nielsen, and T. Katzenstein. 1998. Saquinavir/ritonavir may have better antiviral efficacy than either ritonavir or indinavir in HIV infected antiretroviral naive patients resistance. Presented at the 12th World Congress on AIDS.
53. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1995. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generations. Science 271:1582-1586.
54. Polyak, B., D. B. Henley, J. Maudlin, M. Postelnick, and R. Hirschtick. 1997. The clinical incidence of nephrolithiasis in HIV-positive patients receiving indinavir, abstr. I-183, p. 277. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
55. Rhone, S. A., R. S. Hogg, B. Yip, C. Sherlock, B. Conway, M. V. O'Shaughnessy, M. T. Schechter, and J. S. G. Montaner. 1997. The antiviral effect ritonavir and saquinavir among HIV infected adults: preliminary results from a community based study, abstr. I-207, p. 282. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
56. Rockstroh, J. 1998. Ritonavir plus indinavir - Vierfach-Kombinatherapie als firstline. Internationaler Workshop. HIV-Therapie. Compliance und Wirksamkeit.
57. Rowland, M., and T. N. Tozer. 1989. Clinical pharmacokinetics: concepts and applications, 2nd ed. p. 255-273. Lea & Febiger, Philadelphia, Pa.
58. Saah, A., S. Riddler, D. V. Havir, K. Squires, R. Anderson, B. Kerr, K. Yeh, and P. Deutsch. 1998. Coadministration of indinavir and nelfinavir; pharmacokinetics, tolerability, anti-viral activity, and preliminary viral resistance. Presented at the 12th World Congress on AIDS.
59. Sarcletti, M., A. Petter, K. Lhotta, P. Konig, and R. Zangerle. 1998. Increased risk of indinavir nephrolithiases in women, abstr. 418. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
60. + T-cell counts in HIV infected patients. Ann. Intern. Med. 124:1039-1050.
61. Talal, A., Y. Cao, A. Hurley, R. Schluger, L. Fischer, M. Salgo, L. Smiley, A. Keller, and D. D. Ho. 1997. Saquinavir in combination with AZT/3TC and ritonavir: a convienient BID regimen, abstr. I-208, p. 282. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
62. Watkins, P. B., S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian. 1987. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80:1029-1036.
63. Workman, C., R. Musson, W. Dyer, and J. Sullivan. 1998. Novel double protease combinations-combining indinavir (IDV) with ritonavir (RTV): results from first study. Presented at the 12th World Congress on AIDS.
64. Yeh, K. C., P. J. Deutsch, H. Haddix, M. Hesney, V. Hoagland, W. D. Ju, S. J. Justice, B. Osborne, A. T. Sterrett, J. A. Sone, E. Woolf, and S. Waldman. 1998. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob. Agents Chemother. 42:332-338.